Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren’s Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction
This case highlights the potential of molecular hydrogen (H<sub>2</sub>) therapy as a safe, effective adjunct in managing overlapping Sjögren's syndrome, SLE, and ILD. H<sub>2</sub> therapy improved immune profiles and stabilized symptoms in a patient unresponsive to standard treatments.
Authors
- Yi‐Jung Ho (ORCID: https://orcid.org/0009-0006-3931-2302)
- Yuan-Ju Li
- SHAN-WEN LUI (ORCID: https://orcid.org/0009-0002-1151-6814)
- KUANG-YIH WANG
- Jeng‐Wei Lu (ORCID: https://orcid.org/0000-0003-2128-2046)
- Fen Chang
- Feng‐Cheng Liu (ORCID: https://orcid.org/0000-0003-1291-8946)
- Jinfu Tu (ORCID: https://orcid.org/0000-0002-0580-3932)
- Y. T. Tsai
- H. Hsu
- TING-YU HSIEH
Institutions
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- National Defense Medical Center (TW)
Publication Details
- Journal
- In Vivo
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/invivo.14018
- Citations
- 1
- Primary Topic
- Hydrogen's biological and therapeutic effects
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Tri-Service General Hospital
- National Science and Technology Council